Protagonist Therapeutics

Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced a significant expansion of its hematology portfolio with the acquisition of partial commercial rights to Protagonist Therapeutics Inc.’s investigational drug rusfertide in the U.S., and full rights outside the country. The agreement entails an upfront payment of USD 300 million to the…